BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19
Rui-Ru Ji, Yajin Qu, Huachen Zhu, Yumei Yang, Annette B. Vogel, Uğur Şahin, Chuan Qin, Ai‐Min Hui
Abstract
BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2, which correlated with viral clearance and alleviated lung lesions in these mice after viral challenge.
Topics & Concepts
ImmunogenicityVirologyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakNeutralizing antibodyTiterMedicineImmunizationAntibodyImmunologyVirusOutbreakPathologyInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiologyAnimal Virus Infections Studies